Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Recurrence

NCT03620123 2022-11-18

OPTIM

Phase 2 Completed

54 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

NCT04913922 2022-11-08

AARON

Phase 2 Unknown

30 enrolled

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03825367 2022-10-12

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Phase 1/2 Unknown

13 enrolled

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT03132038 2022-01-11

NISCAHN

Phase 2 Completed

98 enrolled

Head & Neck

Neoplasm Metastasis, Recurrence, Salivary Gland Neoplasms

NCT03023527 2018-05-23

Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma

Phase 1 Terminated

6 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT02962804 2018-03-05

Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)

Phase 2 Withdrawn

Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Recurrence

Clinical Trials

HESTIA

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

PRiME II

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

GlitIpNi

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

LOGICAN

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors